vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and ECB Bancorp, Inc. (ECBK). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $9.5M, roughly 1.6× ECB Bancorp, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs 1.8%, a 25.5% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs 11.5%). ECB Bancorp, Inc. produced more free cash flow last quarter ($9.0M vs $-2.0M). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
CSBR vs ECBK — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $9.5M |
| Net Profit | $268.0K | $2.6M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 36.7% |
| Net Margin | 1.8% | 27.3% |
| Revenue YoY | 11.5% | 33.8% |
| Net Profit YoY | -63.2% | 79.5% |
| EPS (diluted) | $0.02 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $9.5M | ||
| Q3 25 | $14.0M | $8.8M | ||
| Q2 25 | $12.4M | $8.0M | ||
| Q1 25 | $17.0M | $6.9M | ||
| Q4 24 | $13.5M | $7.1M | ||
| Q3 24 | $14.1M | $6.6M | ||
| Q2 24 | $14.0M | $6.3M | ||
| Q1 24 | $12.0M | $6.2M |
| Q4 25 | $268.0K | $2.6M | ||
| Q3 25 | $-436.0K | $2.4M | ||
| Q2 25 | $-1.8M | $1.4M | ||
| Q1 25 | $4.5M | $1.3M | ||
| Q4 24 | $728.0K | $1.4M | ||
| Q3 24 | $1.3M | $1.1M | ||
| Q2 24 | $-109.0K | $791.0K | ||
| Q1 24 | $-2.5M | $621.0K |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 36.7% | ||
| Q3 25 | -3.8% | 37.0% | ||
| Q2 25 | -16.2% | 23.9% | ||
| Q1 25 | 26.4% | 24.9% | ||
| Q4 24 | 5.4% | 27.3% | ||
| Q3 24 | 9.5% | 23.3% | ||
| Q2 24 | -1.9% | 16.9% | ||
| Q1 24 | -21.4% | 13.4% |
| Q4 25 | 1.8% | 27.3% | ||
| Q3 25 | -3.1% | 27.7% | ||
| Q2 25 | -14.9% | 18.0% | ||
| Q1 25 | 26.4% | 18.7% | ||
| Q4 24 | 5.4% | 20.3% | ||
| Q3 24 | 9.3% | 17.2% | ||
| Q2 24 | -0.8% | 12.6% | ||
| Q1 24 | -21.1% | 10.0% |
| Q4 25 | $0.02 | $0.32 | ||
| Q3 25 | $-0.03 | $0.29 | ||
| Q2 25 | $-0.12 | $0.17 | ||
| Q1 25 | $0.31 | $0.16 | ||
| Q4 24 | $0.05 | $0.18 | ||
| Q3 24 | $0.09 | $0.14 | ||
| Q2 24 | $-0.01 | $0.09 | ||
| Q1 24 | $-0.19 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $82.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $171.9M |
| Total Assets | $30.2M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $82.8M | ||
| Q3 25 | $10.3M | $201.9M | ||
| Q2 25 | $9.8M | $191.0M | ||
| Q1 25 | $3.2M | $143.7M | ||
| Q4 24 | $2.8M | $309.4M | ||
| Q3 24 | $2.9M | $114.8M | ||
| Q2 24 | $2.6M | $108.7M | ||
| Q1 24 | $4.5M | $109.8M |
| Q4 25 | $4.2M | $171.9M | ||
| Q3 25 | $3.5M | $169.3M | ||
| Q2 25 | $3.8M | $168.3M | ||
| Q1 25 | $5.5M | $168.6M | ||
| Q4 24 | $681.0K | $168.3M | ||
| Q3 24 | $-332.0K | $166.0M | ||
| Q2 24 | $-1.9M | $166.5M | ||
| Q1 24 | $-2.1M | $165.8M |
| Q4 25 | $30.2M | $1.6B | ||
| Q3 25 | $30.5M | $1.6B | ||
| Q2 25 | $32.3M | $1.5B | ||
| Q1 25 | $30.6M | $1.5B | ||
| Q4 24 | $25.2M | $1.4B | ||
| Q3 24 | $24.9M | $1.4B | ||
| Q2 24 | $26.1M | $1.3B | ||
| Q1 24 | $26.8M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $9.2M |
| Free Cash FlowOCF − Capex | $-2.0M | $9.0M |
| FCF MarginFCF / Revenue | -13.1% | 94.7% |
| Capex IntensityCapex / Revenue | 1.6% | 2.2% |
| Cash ConversionOCF / Net Profit | -6.47× | 3.55× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $9.2M | ||
| Q3 25 | $600.0K | $4.0M | ||
| Q2 25 | $6.9M | $1.9M | ||
| Q1 25 | $490.0K | $-631.0K | ||
| Q4 24 | $-283.0K | $6.2M | ||
| Q3 24 | $311.0K | $861.0K | ||
| Q2 24 | $-1.8M | $1.4M | ||
| Q1 24 | $-919.0K | $-429.0K |
| Q4 25 | $-2.0M | $9.0M | ||
| Q3 25 | $554.0K | $4.0M | ||
| Q2 25 | $6.6M | $1.8M | ||
| Q1 25 | $448.0K | $-649.0K | ||
| Q4 24 | $-377.0K | $6.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | $1.3M | ||
| Q1 24 | $-1.0M | $-449.0K |
| Q4 25 | -13.1% | 94.7% | ||
| Q3 25 | 4.0% | 44.9% | ||
| Q2 25 | 53.5% | 23.0% | ||
| Q1 25 | 2.6% | -9.4% | ||
| Q4 24 | -2.8% | 86.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | 21.4% | ||
| Q1 24 | -8.4% | -7.2% |
| Q4 25 | 1.6% | 2.2% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 2.0% | 0.6% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.7% | 0.8% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.6% | ||
| Q1 24 | 0.8% | 0.3% |
| Q4 25 | -6.47× | 3.55× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | 0.11× | -0.49× | ||
| Q4 24 | -0.39× | 4.31× | ||
| Q3 24 | 0.24× | 0.76× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
ECBK
Segment breakdown not available.
